2018 Prioritization Report

Prioritization of HIV and Hepatitis C medicines for in-licensing by the Medicines Patent Pool.
Comments are welcome and encouraged. Please send an email to info@medicinespatentpool.org with subject line “Comments on the 2018 Prioritization Report”.

The MPP focuses on increasing access to HIV, hepatitis C and tuberculosis medicines. Since our creation in 2010, we have published a list of priority HIV treatments for our licensing programme. In 2017, we expanded our evaluation to include important treatments for hepatitis C. Our method for prioritising, developed with support from a broad range of experts, is based on four criteria:

  • The medicine’s clinical importance
  • The extent to which the treatment is patented in developing countries
  • Existing licensing agreements in place
  • The potential for market uptake.

Target medicines may include those already in the market as well as investigational candidates. The focus is on medicines that are not yet licensed to the MPP.

_________________________________________________________________________________________________________________________________________________________

The 2018 Prioritization Report selected one HIV, one hepatitis C and three tuberculosis compounds that, if successfully developed, could improve standard of care for people living in developing countries.

Current target products and formulations:

HIV prioritization
Cabotegravir

 

HCV prioritization
Glecaprevir/pibrentasvir

 

Tuberculosis prioritization
Bedaquiline
Delamanid
Pretomanid

 

In addition, the following HIV products have been included in an MPP Watchlist:

HIV
Doravirine
Fostemsavir
Rilpivirine long-acting injectable

 

The status of negotiations on priority products will be updated on a quarterly basis in line with MPP’s Transparency Policy.

Annex to the 2018 Prioritization Report: HIV and HCV pipelines compiled by the MPP

This website uses cookies to ensure you get the best experience on our website. Learn More